Triolab supplies equipment for the healthcare sector and is a leader in human diagnostics, with more than 30 years of experience on the Swedish market. The company operates in the customer segments that are important to Calmark, and sells, among other things, blood gas analyzers for maternity wards and intensive care units.

"Triolab is exactly the kind of partner we want to work with; they are experts in diagnostics, they address the specific customer segments that we are focusing on, and they are at the forefront, desiring to offer the latest point-of-care analysis methods," explains Marianne Alksnis, International Sales Director at Calmark.

"We are always endeavouring to offer our customers high-quality products that provide better value for patients. Analytic quality, usability and quick results are key factors in POC diagnostics. Calmark Neo will give our customers access to a unique test platform for newborn patients," says Anna Bergström, VP of Triolab. "We are eager to cooperate with a partner that shares our ambition to improve the care for newborn infants."

"We are so happy that this deal has now been finalized," says Anna Söderlund, CEO of Calmark. "We are looking forward to launching sales on our home market through this cooperation with such a strongly established distributor."

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 14 February 2020, 12:30 CET.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
 

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 213 25 35
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analyzis method with easier and faster sampling of medical conditions in newborns. The unique test platform, which consists of a reader and single-use products, is expected to be ready for launch in 2020 when three important POC tests are introduced. The WHO estimates that 1.5 billion children will be born worldwide by 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter healthcare chains. In less developed healthcare systems, the product helps save lives. Calmark aims to become the global leader and ultimately to offer all relevant POC tests for the first period of life, regardless of where in the world a baby is born. Read more about Calmark www.calmark.se/eng/home.